Hope S. Rugo, MD

Professor of Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Authored Items
HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms
Hope S. Rugo, MD
Videos in Breast Cancer, Video
CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
Hot Topics at SABCS 2017
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
HER2+ Breast Cancer and CDK4/6 Inhibitors
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
Last modified: December 5, 2017